These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 23740440)

  • 1. Can we prevent, reduce or reverse intestinal fibrosis in IBD?
    Latella G; Sferra R; Speca S; Vetuschi A; Gaudio E
    Eur Rev Med Pharmacol Sci; 2013 May; 17(10):1283-304. PubMed ID: 23740440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of initiation and progression of intestinal fibrosis in IBD.
    Latella G; Di Gregorio J; Flati V; Rieder F; Lawrance IC
    Scand J Gastroenterol; 2015 Jan; 50(1):53-65. PubMed ID: 25523556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of non-inflammatory factors in intestinal fibrosis.
    Zhao JF; Ling FM; Li JR; Chen YD; Huang L; Zhu LR
    J Dig Dis; 2020 Jun; 21(6):315-318. PubMed ID: 32406603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Features of intestinal lesions in the clinical course of inflammatory bowel diseases.
    Vetuschi A; Latella G; Pompili S; Gaudio E; Sferra R
    Ital J Anat Embryol; 2014; 119(3):286-303. PubMed ID: 26749690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PPAR-γ with its anti-inflammatory and anti-fibrotic action could be an effective therapeutic target in IBD.
    Vetuschi A; Pompili S; Gaudio E; Latella G; Sferra R
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8839-8848. PubMed ID: 30575926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of Intestinal Fibrosis in Inflammatory Bowel Disease and Perspectives for Therapeutic Implication.
    Bettenworth D; Rieder F
    Dig Dis; 2017; 35(1-2):25-31. PubMed ID: 28147352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of the 4th scientific workshop of the ECCO (I): pathophysiology of intestinal fibrosis in IBD.
    Latella G; Rogler G; Bamias G; Breynaert C; Florholmen J; Pellino G; Reif S; Speca S; Lawrance IC
    J Crohns Colitis; 2014 Oct; 8(10):1147-65. PubMed ID: 24731838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intestinal fibrosis in IBD--a dynamic, multifactorial process.
    Rieder F; Fiocchi C
    Nat Rev Gastroenterol Hepatol; 2009 Apr; 6(4):228-35. PubMed ID: 19347014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenic aspects and therapeutic avenues of intestinal fibrosis in Crohn's disease.
    Zorzi F; Calabrese E; Monteleone G
    Clin Sci (Lond); 2015 Dec; 129(12):1107-13. PubMed ID: 26494636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: anti-fibrotic agents for the treatment of Crohn's disease - lessons learnt from other diseases.
    Szabò H; Fiorino G; Spinelli A; Rovida S; Repici A; Malesci AC; Danese S
    Aliment Pharmacol Ther; 2010 Jan; 31(2):189-201. PubMed ID: 19832726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of tissue remodeling in inflammatory bowel disease.
    Rieder F; Fiocchi C
    Dig Dis; 2013; 31(2):186-93. PubMed ID: 24030223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventing fibrosis in IBD: update on immune pathways and clinical strategies.
    Wang J; Yang B; Chandra J; Ivanov A; Brown JM; Rieder F
    Expert Rev Clin Immunol; 2024 Jul; 20(7):727-734. PubMed ID: 38475672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation.
    Kanazawa S; Tsunoda T; Onuma E; Majima T; Kagiyama M; Kikuchi K
    Am J Gastroenterol; 2001 Mar; 96(3):822-8. PubMed ID: 11280558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal fibrosis: ready to be reversed.
    Latella G; Rieder F
    Curr Opin Gastroenterol; 2017 Jul; 33(4):239-245. PubMed ID: 28402994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nr4A1 modulates inflammation-associated intestinal fibrosis and dampens fibrogenic signaling in myofibroblasts.
    Pulakazhi Venu VK; Alston L; Iftinca M; Tsai YC; Stephens M; Warriyar K V V; Rehal S; Hudson G; Szczepanski H; von der Weid PY; Altier C; Hirota SA
    Am J Physiol Gastrointest Liver Physiol; 2021 Sep; 321(3):G280-G297. PubMed ID: 34288735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New therapeutic avenues for treatment of fibrosis: can we learn from other diseases?
    Rogler G
    Dig Dis; 2014; 32 Suppl 1():39-49. PubMed ID: 25531352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significant contribution of TRPC6 channel-mediated Ca
    Kurahara LH; Hiraishi K; Sumiyoshi M; Doi M; Hu Y; Aoyagi K; Jian Y; Inoue R
    J Smooth Muscle Res; 2016; 52(0):78-92. PubMed ID: 27818466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases.
    Rieder F; Fiocchi C; Rogler G
    Gastroenterology; 2017 Feb; 152(2):340-350.e6. PubMed ID: 27720839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects.
    Papa A; Scaldaferri F; Danese S; Guglielmo S; Roberto I; Bonizzi M; Mocci G; Felice C; Ricci C; Andrisani G; Fedeli G; Gasbarrini G; Gasbarrini A
    Dig Dis; 2008; 26(2):149-55. PubMed ID: 18431065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological Regulation of Intestinal Fibrosis in Inflammatory Bowel Disease.
    Bamias G; Pizarro TT; Cominelli F
    Inflamm Bowel Dis; 2022 Mar; 28(3):337-349. PubMed ID: 34904152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.